{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=12&q=gastroesophageal+junction", "query": { "q": "gastroesophageal junction", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 518, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=13&q=gastroesophageal+junction&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=11&q=gastroesophageal+junction&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T01:12:49.433Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06219941", "title": "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "AZD0901", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "l-leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Nanoliposomal Irinotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2023-12-13", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Santa Rosa, California + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06219941" }, { "nct_id": "NCT03102320", "title": "Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Anetumab ravtansine (BAY94-9343)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2017-05-26", "completion_date": "2021-07-26", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Los Angeles, California • Stanford, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03102320" }, { "nct_id": "NCT05259696", "title": "Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology", "Melanoma", "Ovarian Cancer", "NSCLC", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Cancer", "CRC", "Colon Cancer", "Breast Cancer", "Gastric Cancer", "EGJ", "Esophagogastric Junction Cancer", "Head and Neck Cancer", "Urothelial Cancer", "Bladder Cancer" ], "interventions": [ { "name": "E-602", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Palleon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2022-02-11", "completion_date": "2024-10-24", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 13, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05259696" }, { "nct_id": "NCT04361708", "title": "Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Adenocarcinoma" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2020-05-08", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04361708" }, { "nct_id": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumors", "Non-small Cell Lung Cancer", "Melanoma", "Head and Neck Squamous Cell Carcinoma", "Gastric Adenocarcinoma", "Renal Cell Carcinoma", "Esophageal Adenocarcinoma", "Nasopharyngeal Carcinoma", "Oropharyngeal Carcinoma" ], "interventions": [ { "name": "INBRX-105 - PDL1x41BB antibody", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inhibrx Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2019-01-30", "completion_date": "2024-10-03", "has_results": false, "last_update_posted_date": "2024-10-23", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03809624" }, { "nct_id": "NCT06299163", "title": "NM32-2668 in Adult Patients With Selected Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Peritoneal Carcinoma", "Endometrial Cancer", "Adenocarcinoma of Lung", "Triple Negative Breast Cancer", "Liposarcoma", "Leiomyosarcoma", "Mesothelioma, Malignant", "Adenocarcinoma - Gastroesophageal Junction (GEJ)", "Adenocarcinoma of the Stomach", "Melanoma, Malignant", "Renal Cell Carcinoma" ], "interventions": [ { "name": "NM32-2668", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Numab Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2024-05-01", "completion_date": "2025-04-18", "has_results": false, "last_update_posted_date": "2025-07-23", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06299163" }, { "nct_id": "NCT04580485", "title": "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Bladder Cancer", "Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer", "Castration Resistant Prostate Cancer", "Colorectal Cancer", "Gastric/ Gastroesophageal Junction", "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Squamous Carcinoma of the Anal Canal" ], "interventions": [ { "name": "INCB106385", "type": "DRUG" }, { "name": "INCMGA00012", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-02-03", "completion_date": "2024-01-22", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 8, "location_summary": "West Hollywood, California • Baltimore, Maryland • Boston, Massachusetts + 5 more", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04580485" }, { "nct_id": "NCT07529808", "title": "Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma", "Gastric (Stomach) Cancer", "Gastroesophageal Adenocarcinoma", "Gastroesophageal Cancer (GC)", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Gastroesophageal Junction (GEJ) Cancer", "Gastrointestinal Cancer Metastatic", "Gastrointestinal Adenocarcinoma", "Gastrointestinal Cancers", "Colorectal (Colon or Rectal) Cancer", "Pancreatic Cancer", "CDH17-positive Advanced Solid Tumors", "Advanced Gastric Cancer" ], "interventions": [ { "name": "BHB810", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BigHat Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2026-07-16", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 3, "location_summary": "Duarte, California • Santa Monica, California • Fairfax, Virginia", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07529808" }, { "nct_id": "NCT07488676", "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "ASP546C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2026-05-04", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07488676" }, { "nct_id": "NCT03175224", "title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Cancer", "Renal Cancer", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "NSCLC", "Lung Cancer", "Brain Tumor", "Glioblastoma Multiforme", "EGFR Gene Mutation", "MET Amplification", "HGF", "Thyroid Cancer", "Pancreatic Cancer", "Colon Cancer", "MET Alteration", "MET Fusion", "Exon 14 Skipping" ], "interventions": [ { "name": "APL-101 Oral Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apollomics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 497, "start_date": "2017-09-27", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-10-14T01:12:49.433Z", "location_count": 6, "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03175224" } ] }